Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine

A compound of Formula (IA):

• 245
• wherein:
• a is 0 and b is 0;
• or a is 1 and b is 0;
• or a is 1 and b is 1;
• Y is selected from N and N→O;
• one of R1, R2 and R3 is a ring moiety selected from C4-6 cycloalkyl, phenyl, naphthyl, C1-5 heterocyclyl, (C4-6 cycloalkyl)C1-3 alkylene, (phenyl)C1-3alkylene, (naphthyl) C1, alkylene, and (C1-5 heterocyclyl)C1-3 alkylene;
• and the remaining two of R1, R2 and R3 are independently selected from hydrogen, halogen, and C1, alkyl;
• wherein said ring moiety is substituted with a moiety of formula:
• —X-W-Z, X-Z, W-Z or Z;
• wherein X is selected from the group consisting of O, S, SO2, SO, NR4, —CH═CH—, —C═C—, —OCH2—C═C—, —C═C—CH2O—, —CH(R5)—, CO, —O—CO—, —CO—O—, CHOH, —NR4—CO—, —CO—NR4—, —SO2—NH—, —NR4—SO2—, and —SO2—NR4—;
• R4 is H, or C1-6 alkyl;
• R5 is H, C1-6alkyl, or hydroxy;
• W is C1-6 alkylene, phenylene, (phenylene)(C1-3 alkylene), or —CH2—CHCH—CH2—;
• Z is selected from:
• (i) NR21R22, NHCOR23, or NHSO2R23,
• (ii) C3-6 heterocyclyl or C7-12 fused bicyclyl, and
• (iii) phenyl substituted with a C3-6 heterocyclyl group, or with a (C3-6 heterocyclyl)C1-6 alkylene group,
• wherein each phenyl or heterocyclyl group in (ii) or (iii) may be substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, C1-6 alkyl, C1-6 alkoxy, cyclohexyl, cyclohexenyl, phenyl, (phenyl)C1-6 alkylene, trihalo C1-6alkyl, nitro, SCH3, NR21R22, amido, amidino, amino C1-6 alkyl, acetylene, CHR23R24, COR23, acetyl, NHCOCH3, C3-6 heterocyclyl, (C3-6 heterocyclyl) C1-6 alkylene, cyano, NHSO2CH3, N(SO2CH3)2, carboxy, C1-6 alkoxycarbonyl, amidoxime, trihalo C1-6 alkoxy, oxo, hydroxyiminomethyl, C1-6 alkylcarboxy, carboxy C1-6 alkyl, trihaloacetyl, and methylsulfonyl;
• wherein each of R21 and R22 is independently selected from H, C1-6 alkyl, C4-7 cycloalkyl, phenyl, benzyl, C1-6 alkoxy, hydroxy, C1-6 alkylamino, di(C1-6)alkylamino, C2-8 acyl, C1-8 alkylsulfonyl;
• R23 is C1-6alkyl, C4-7 cycloalkyl, phenyl, benzyl, C1-6 alkoxy, hydroxy, aryl, C1-6 alkylamino, di(C1-6)alkylamino, C2-8 acyl, C1-8 alkylsulfonyl;
• R24 is H, halogen, hydroxy, amino, C1-6 alkyl, C4-7 cycloalkyl, phenyl, or benzyl;
• in addition, said R1, R2 or R3 that is a ring moiety is optionally substituted with between 1 and 3 substituents Q1, Q2, and Q3, which, if present, are independently selected from:
• R25, NR26R27, NHCOR28, NHSOR29, and NHSO2R30;
• wherein R25 is H, C1-6 alkyl, C4-7 cycloalkyl, phenyl, benzyl, C1-6 alkoxy, hydroxy, C1-6 alkylamino, di(C1-6)alkylamino, C2-8 acyl, or C1-8 alkylsulfonyl;
• wherein each of R26 and R27 is independently selected from H, C1-6 alkyl, C4-7 cycloalkyl, phenyl, benzyl, C1-6 alkoxy, hydroxy, C1-6 alkylamino, di(C1-6)alkylamino, C2-8 acyl, C1-8 alkylsulfonyl;
• each of R28, R29, and R30 is C1-6 alkyl, C4-7cycloalkyl, phenyl, benzyl, C1-6 alkoxy, hydroxy, C1-6 alkylamino, di(C1-6)alkylamino, C2-8 acyl, C1-8 alkylsulfonyl;
• and
• R11, R12, R14 and R15 are each independently selected from hydrogen, halogen, C1-6 alkyl and C1-6 alkoxy;
• R13 is selected from hydrogen, oxo, and phenyl;
• R16 is selected from hydrogen, cyano, C1-6 alkyl, and C1-6 alkylamino;
• wherein each of the above carbocyclyl and heterocarbocyclyls can be optionally substituted with between 1 and 3 substituents selected from C1-4 alkyl, hydroxy, amino, halo, C, alkoxy, CONH2, phenyl, and C1-4 alkylamino, di(C1-4)alkylamino;
• and wherein —X-W-Z is not [4-(imidazol-1yl)-phenyl]oxy where a is 1 and b is 0;
• or a pharmaceutically acceptable salt, ester, or amide thereof.